St. Jude Children's Research Hospital
Primary Objective: To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives: To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
This is a Phase I clinical trial evaluating the safety of escalating doses of CD7 negative T cells expressing CD7-CARs in patients with high-risk hematological malignancies. Patients will receive 3 days of lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide. Following this, patients will receive a single infusion of CD7-CAR T cells (with dosing based on the number of CAR+ T cells and patient weight). There will be 3 escalating dose levels on the study and clearly defined dose escalation criteria are outlined.
Procurement and T-cell production Eligibility\* \*a previously frozen, autologous leukapheresis product can be used for T-cell production Recipient Inclusion * Age ≤21 years old * Relapsed/refractory CD7+ AML * Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR) * Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy. * Relapsed/refractory T-cell ALL/lymphoma * Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR) * Refractory disease: Patients with persistent…
Day 4, 3, 2 at 40 mg/m2 dose. Intravenous.
Day -2 at 90mg/m2 dose. Intravenous infusion.
CD7-CAR T-cell infusion
Given intravenously divided as 4 doses equal to 25% cyclophosphamide dose per dose of Mesna administered prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.